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Abstract
Background: D-aspartic acid is an amino acid present in neuroendocrine tissues of invertebrates
and vertebrates, including rats and humans. Here we investigated the effect of this amino acid on
the release of LH and testosterone in the serum of humans and rats. Furthermore, we investigated
the role of D-aspartate in the synthesis of LH and testosterone in the pituitary and testes of rats,
and the molecular mechanisms by which this amino acid triggers its action.
Methods: For humans: A group of 23 men were given a daily dose of D-aspartate (DADAVIT®)
for 12 days, whereas another group of 20 men were given a placebo. For rats: A group of 10 rats
drank a solution of either 20 mM D-aspartate or a placebo for 12 days. Then LH and testosterone
accumulation was determined in the serum and D-aspartate accumulation in tissues. The effects of
D-aspartate on the synthesis of LH and testosterone were gauged on isolated rat pituitary and
Leydig cells. Tissues were incubated with D-aspartate, and then the concentration (synthesis) of
LH and cGMP in the pituitary and of testosterone and cAMP in the Leydig cells was determined.
Results: In humans and rats, sodium D-aspartate induces an enhancement of LH and testosterone
release. In the rat pituitary, sodium D-aspartate increases the release and synthesis of LH through
the involvement of cGMP as a second messenger, whereas in rat testis Leydig cells, it increases the
synthesis and release of testosterone and cAMP is implicated as second messenger. In the pituitary
and in testes D-Asp is synthesized by a D-aspartate racemase which convert L-Asp into D-Asp. The
pituitary and testes possesses a high capacity to trapping circulating D-Asp from hexogen or
endogen sources.
Conclusion: D-aspartic acid is a physiological amino acid occurring principally in the pituitary gland
and testes and has a role in the regulation of the release and synthesis of LH and testosterone in
humans and rats.
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Background
D-Aspartic acid (D-Asp) is an endogenous amino acid
which has been found in the neuroendocrine tissues of
both invertebrates and vertebrates [1]. D-Asp was first
found in the nervous system of marine mollusks [2] and
subsequently in the nervous and endocrine tissues of
many other animals, including humans [1]. High levels of
D-Asp occur transiently in the brain of chickens, rats and
humans during the last stage of embryonic life, suggesting
that it has a role in the development of the nervous system
[3-6]. In addition, within the nervous system this amino
acid is concentrated in the axon terminals (synapto-
somes) and in synaptic vesicles together with L-Asp and L-
Glu [7]; additionally, it is involved in visual activity [8],
suggesting it has a role in neurotransmission.
In the endocrine system, high concentrations of D-Asp
have been recorded in rat testes at birth as well as follow-
ing sexual maturity [5]. Further research involving rats
showed the highest concentrations of D-Asp in testicular
venous blood plasma, as well as in the rete testis, the
epididimus, testicular parenchymal cells, seminiferous
tubules, interstitial fluid and spermatozoa [9], suggesting
that D-Asp is involved in spermatogenesis. A specific D-
Asp localization was further observed in rat testes either in
elongate spermatidits [10] or in Leydig cells [11]. Several
further studies have demonstrated that D-Asp is concen-
trated in the endocrine gland, particularly in the pineal
gland, the pituitary and the testis [1,12]. It has been
observed that D-Asp in rats is capable of eliciting the
release of the gonadotropin-releasing hormone (GnRH)
from the hypothalamus, the luteinizing hormone (LH)
and the growth hormone (GH) from the pituitary gland,
and testosterone from the testes [13]. In addition, D-Asp
occurs in a high concentration in the pineal gland [14],
where it modulates melatonin synthesis in rat pinealo-
cytes [15], and is implicated in the α-melanocyte-stimu-
lating hormone, GABA, and in dopamine release [16]. In
sheep, D-Asp is endogenously present in tissues and is
electively stored in endocrine glands, such as the pituitary,
and in the brain after its administration. NMDA and LH
increased following D-Asp administration [17]. Recently
an in vitro study carried out on boar testes revealed that
endogenous testicular D-Asp enhances gonad aromatase
activity [18], the key enzyme that converts testosterone
into 17β-estradiol. In addition, studies done on the testes
and ovary of the lizard Podarcis s. sicula have shown simi-
lar findings, confirming that D-Asp is involved in the local
production of estrogen [19,20].
On the basis of the above findings, D-Asp seems to play a
crucial role in reproduction either due to its suggested role
of neuromodulator or because it is involved in biosynthe-
sis and the release of sexual hormones. Recent studies ana-
lyzed the role of D-Asp in human reproduction in both
females and males. In men, a lower D-Asp content was
found in oligoasthenoteratospermic seminal fluid and
spermatozoon, and a relationship exists between the
amount and motility of semen and the content of D-Asp
[21]. In women, it has been found that D-Asp occurs in
the follicular fluid as a physiological component, and
interestingly, the concentration of D-Asp in the fluid is
reduced in older women. In addition, the concentration
of D-Asp in the follicular fluid is lower, as are the quality
of the oocytes and the level of fertilization [22].
Although numerous studies have been conducted on this
matter, no investigations have been done until now on
the effects of D-Asp on the secretion of LH and testoster-
one in humans, and neither has the molecular mecha-
nism by which D-Asp triggers it action in the synthesis and
release of these hormones been investigated. This study
aims to evaluate the effects of D-aspartate administration
on LH and testosterone production in humans and rats
and to understand the biochemical mechanisms by which
D-Asp induces the synthesis and release of LH and testo-
sterone, using rats as the model animal.
Methods
Determination of D-Asp by HPLC associate with D-AspO
The determination of D-Asp in serum and tissues was car-
ried out using an HPLC enzymatic method combined
with D-aspartate oxidase (D-AspO) according to our pre-
viously described method [8]. For the serum, 0.4 ml
serum was mixed with 3.6 ml of 0.2 M TCA and centri-
fuged at 10,000 g for 10 min. The supernatant was puri-
fied on cation exchange resin (AG 50WX8). The purified
sample was dissolved in 0.4 ml H2O and then 50 μl were
used for HPLC according to the described method [8]. For
solid tissues 10-100 mg tissues were homogenized at a
ratio of 1:50 with 0.1 M TCA and centrifuged as above.
The supernatant was purified as above and analyzed at
HPLC as described [8]. In order to quantify the content in
amino acids in the sample, a standard curve consisting of
50 pmoles of D-Asp and 100 pmoles of each of the follow-
ing amino acids: L-Asp, L-Glu, L-Ser, L-Thr, L-His, Gly, L-
Arg, L-Ala, L-Val, L-Met, L-Tyr, L-Phe, L-Ile, L-Leu and L-
Lys was carried out in the same assay condition. The
method allowed the determination with high reliability of
a minimum amount of D-Asp at a coefficient of variation
(CV) of 5% as calculated from 10 repeated analyses of D-
Asp from a sample in which a known amount of D-Asp
has been added.
Effects of D-aspartate on LH and testosterone in serum 
release in humans and rats
The experiment using human subjects was carried out on
two groups of healthy male volunteers aged between 27
and 37 years at the IVF (in vitro fertilization) Unit, Hospi-
tal "S. Luca", Vallo della Lucania, Italy. The first group wasReproductive Biology and Endocrinology 2009, 7:120 http://www.rbej.com/content/7/1/120
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composed of 23 volunteers who constituted the experi-
mental group; the second group was composed of 20 vol-
unteer who constituted the placebo group. Informed
consent was obtained from each participant and the pro-
cedure was approved by the Institutional Review Board of
the Hospital. Every morning at breakfast for 12 consecu-
tive days subjects in the first group were invited to con-
sume, by mouth a solution of 10 ml of 2.0 M sodium D-
aspartate (3.12 g/10 ml) supplemented with vitamin B6,
folic acid and vitamin B12 and diluted in half a glass of
water or fruit juice. This solution is marketed in Italy
under the name DADAVIT® (Pharmaguida s.r.l., Italy) and
used as a supplement to increase the quality of human
seminal fluid. The participants belonging to the placebo
group received 10 ml of a solution consisting of 2 M NaCl
(1.12 g/10 ml in water) containing the same vitamins as
above, and this solution was packaged as DADAVIT® solu-
tion (termed DADAVIT® placebo). Blood samples (8-10
ml) from each participant were taken before treatment,
after 6 days of treatment, after 12 days of treatment, and 3
days after suspension of the treatment. The blood was
taken in the morning between 9.30 and 10.30 a.m., a time
when serum oscillations of LH and testosterone are at
their minimum value [23]. The determination of LH and
testosterone in human blood was carried out using com-
mercially available immunochemoluminescence kits for
LH and testosterone purchased from Bayer HealthCare
LLC, Subsidiary System (Bayer Corporation, USA).
According to the manufacturing company that have pre-
pared the kits for LH and testosterone, the sensitivity of
the method was 0.1 mIU/ml for LH and 0.2 ng/ml for tes-
tosterone.
The experiments on rats were carried out as follows: Adult
Wistar male rats (120 days old, 340 ± 20 g), purchased
from Charles River laboratory (Italy), were housed 2 per
cage in a controlled environmental animal facility with a
12-h light/dark cycle and fed with laboratory food pellets
and water ad libitum until experimentation. All the proce-
dures involving rats were in accordance with institutional
guidelines. When ready, three groups of 10 animals each
were prepared. Rats in the first group were allowed to
drink a solution consisting of 20 mM of sodium D-aspar-
tate for 12 days and then sacrificed. Rats in the second
group were given to drink a solution of 20 mM sodium D-
aspartate to drink for 12 consecutive days; then allowed to
drink tap water for 3 days and then sacrificed. Rats in of
the third group (control) were given to drink a solution of
20 mM NaCl to drink for 12 days and then sacrificed. After
rats were sacrificed, the blood and solid tissues (frontal
cortex, hippocampus, pituitary, testis, liver and kidney)
were collected. The serum was obtained from the blood
(after coagulation and centrifugation at 3,000 g for 30
min) and the concentration of LH and testosterone (hor-
mone release) determined. The solid tissues were homog-
enized in PBS at a ratio of 1:20 and centrifuged at 10,000
g for 30 min. The supernatant was used for the analysis of
D-Asp by HPLC.
The determination of LH in the rat serum was carried out
using a reagent kit from Amersham Biosciences (EIA
Biotrak™ System RPN 2562; Amersham Biosciences
Europe GmbH, Cologno Monzese, Milano, Italy),
whereas the concentration of testosterone in the rat serum
was determined using the same kits and the same proce-
dure that were used for the human serum.
Effects of D-aspartate on the rat pituitary in the synthesis 
of LH and cGMP: In vitro experiments
The pituitary was taken from an adult male rat (120 days
old) and cut longitudinally into two portions, and then
incubated with moderate shaking at 37°C for 60 min in
1.0 ml of Krebs-Ringer solution, pH 7.4, containing 50 μl
of a cocktail of protease inhibitors (Sigma, P 8340) and
also contained 1 mg/ml BSA in air/CO2 (19:1) and D-Asp
at the concentration of 0.1 mM (10 μl of 10 mM). The
same experiment was repeated using a second male rat,
but D-Asp was at the concentration of 1.0 mM (10 μl of
100 mM). The same experiment was repeated on a third
male rat, but without D-Asp (control). After incubation,
each sample was homogenized in its incubation solution
and divided into two equal portions. The first portion was
centrifuged at 10,000 rpm for 5 min at 4°C, and the
supernatant was used for LH determination (synthesis).
The second portion was mixed with 25 μl of 1 M HCl and
25 μl of 1 M TCA, then homogenized and centrifuged. The
supernatant was neutralized with 1 M NaOH and used for
the determination of cGMP (cyclic guanosine monophos-
phate; 3',5'-cyclic guanosine monophosphate) and cAMP
(cyclic adenosine monophosphate; 3',5'-cyclic adenosine
monophosphate). These determinations were carried out
using a radioimmunoassay based on the competition
between unlabelled cAMP or cGMP and a fixed quantity
of the tritium labeled compound (Amersham Biosciences,
Buckinghamshire, England (cAMP: code TRK432; cGMP:
code TRK500). This experiment was repeated five times
on sample from different animals.
Effects of D-aspartate on rat Leydig cells in the synthesis 
of testosterone and cAMP: In vitro experiments
Leydig cells were prepared from the testes of 5 rats accord-
ing to the described procedure [24]. The purified Leydig
cells were suspended at a concentration of 1 × 106 cells/ml
in Krebs-Ringer solution containing a cocktail of protease
inhibitors (Sigma, P 8340, diluted 1:100) and BSA 1 mg/
ml. To 1 ml of this suspension were added, respectively,
10 μl of 10 mM of sodium D-aspartate and 10 μl of 100
mM of sodium D-aspartate (0.1 and 1.0 mM, respec-
tively). For the control, 10 μl of H2O was used instead of
D-Asp. The samples were incubated for 60 min at 37°CReproductive Biology and Endocrinology 2009, 7:120 http://www.rbej.com/content/7/1/120
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with moderate shaking. Then each sample was homoge-
nized in its solution and divided into two equal portions.
The first portion was centrifuged at 10,000 g for 5 min,
and the supernatant was used for the testosterone deter-
mination. The second portion was mixed with 50 μl of 1
M HCl and 50 μl of 1 M TCA, then homogenized and cen-
trifuged, and the supernatant was used for the determina-
tion of cAMP and cGMP. This experiment was repeated
five independent times.
Biosynthesis of D-aspartate in rat tissues: D-aspartate 
racemase activity
The endogenous presence of D-Asp in rat tissues and in
particular in the pituitary gland and testis has suggested
that this amino acid is synthesized in vivo by an aspartate
racemase (EC 5.1.1.13) which converts L-Asp to D-Asp.
This enzyme has been found in bacteria [25] in mollusks
[7,8,26], in amphibians [19], and in rat neurons [6]. In
this study we determined the activity of this enzyme that
we have termed 'D-Aspartate racemase because it converts
L-Asp into D-Asp, using a modified procedure of the
described method [7]. The procedure consists of two
steps: i) incubation of the sample with L-Asp to generate
D-Asp; and ii) determination of D-Asp by D-AspO with a
colorimetric method. The reactions involved in the entire
procedure are:
Step 1: Rat tissues were homogenized at a ratio of 1:10 in
0.1 M Tris-HCl, pH 8.0, containing 10 mM EDTA, and
centrifuged at 20,000 g for 20 min. Then, 500 μl of the
supernatant was mixed with 500 μl of 0.2 M sodium L-
aspartate and incubated at 37°C for 60 min. A blank was
prepared as a sample, but incubated at 0°C (ice water)
instead of 37°C, for 60 min. After incubation, 200 μl of
1.0 M TCA was added, and the solution was mixed and
centrifuged for 10 min at 20,000 g.
Step 2: 1 ml of each supernatant (sample and blank) was
neutralized with 80-90 μl of 2.0 M NaOH and mixed with
100 μl Tris-HCl 1 M, pH 8.2 and 5 μl of purified D-AspO
(2 mg/ml; 300 U/ml), obtained by over-expression from
beef kidney [8] or from the hepathopancreas of Octopus
vulgaris [2] and incubated for 30 min at 37°C in order to
oxidize the D-Asp in α-oxaloacetate. After that, 100 μl of
5.0 mM 2,4-dinithrophenylhydrazine (in 5 M HCl) was
added, mixed and left at room temperature for 10 min.
Finally, 200 μl of 5 M NaOH was added and mixed, and
the absorbance of the sample was read against the blank
at 445 nm. In order to determine the amount of D-Asp in
the 1 ml of the above supernatant, a standard test of D-
Asp was carried out. For this purpose, 1.0 ml of 0.01 mM
of sodium D-aspartate was mixed with 100 μl of H2O, 100
μl Tris-HCl 1 M, pH 8.2 and 5 μl of purified D-AspO and
the procedure was continued as sample. The absorbance
of this standard was read against a blank in which 1.0 ml
H2O was used instead of D-aspartate. One enzyme unity
(EU) was defined as the amount of the enzyme capable of
generating 1 nmol of D-Asp in 60 min of incubation at
37°C in the above assay conditions. The specific activity
was defined as the EU/mg of the homogenate.
Statistical analysis
Results are presented as the mean ± SEM. LH and testoster-
one concentrations in human serum were analyzed by
analysis of variance with repeated measurements
(ANOVA, StatView). D-Asp storage in rat tissues and LH
and testosterone concentration from in vivo and in vitro
experiments on rats were analyzed by one-way ANOVA.
Pairwise comparison of the means was made with Fisher's
LSD test. Values of p < 0.05 were considered significant.
Results
Specific determination of D-aspartic acid by HPLC-D-
AspO
The determination of free D-Asp in the sample was carried
out using an HPLC method associated with the use of D-
aspartate oxidase (D-AspO), as previously reported [8].
Fig. 1 shows a typical HPLC analysis of a standard mixture
of amino acids and a biological sample. Panel A shows the
HPLC analysis of a mixture consisting of 20 pmoles of D-
Asp and 50 pmoles of various L-amino acids. Panel B,
shows the same HPLC analysis of the amino acid standard
mixture, but after treatment with D-AspO. Panel C shows
the HPLC analysis of free amino acids from 0.05 mg of a
rat hippocampus; and panel D shows the same sample,
but after treatment with D-AspO. This figure shows that in
both the standard mixture (panel B) and the sample
(panel D) the peak of D-Asp disappeared completely after
the incubation of these samples with D-AspO, indicating
that the peak of D-Asp was completely due to D-Asp in the
standard mixture or in the sample, respectively.
Effects of D-aspartate on LH and testosterone release in 
humans
In this study 23 participants took an oral dose of sodium
D-aspartate (DADAVIT®) for 12 consecutive days and 20
participants took an oral dose of placebo (DADAVIT® pla-
cebo) for 12 consecutive days; the levels of LH and testo-
sterone in the serum were monitored after 6 and 12 days
of treatment and 3 days after suspension of the treatment
(with D-aspartate or the placebo).
Concerning the LH pattern, the results demonstrated that
after 12 days of D-Asp treatment, 20 out of 23 (87%) par-
ticipants had significantly increased concentrations of LH
Step 1
Step 2
 L-Aspartate D-Aspartate
 
D-Asp racemase :
:
⎯→ ⎯⎯⎯⎯⎯⎯
D D-Aspartate O H O oxaloacetate H O NH
ox
D-AspO ++ ⎯ → ⎯⎯⎯ ⎯− + +
−
22 2 2 3 a
a a aloacetate dinitrophenylhydrazine oxaloacetate-hydr +− = − 24 , a a azine complex
oxaloacetate-hydrazine complex
yellow colo
a −
(r rd a r k  r e d  c o l o r
NaOH oxaloacetate-hydrazone complex
)( )
+= − aReproductive Biology and Endocrinology 2009, 7:120 http://www.rbej.com/content/7/1/120
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in their blood with respect to basal values (the value of LH
found in the same subjects before starting treatment). Sta-
tistical analysis demonstrated that the value (mean ±
SEM) of serum calculated for all the 23 subjects treated
with D-Asp increased by 33.3%. From a basal-level mean
of 4.2 ± 0.5 mIU/ml, LH rose to a mean value of 5.6 ± 0.9
mIU/ml (Table 1). The increase was statistically signifi-
cant (ANOVA with repeated measures: [F(2,82) = 24.279, p
< 0.0001]). LH concentration determined in the placebo
group after D-Asp treatment compared with the level
before treatment had not increased [ANOVA: F(1,82) =
0.643, p > 0.427]), thus indicating that the increase of LH
due to D-aspartate treatment was authentic. The effect of
D-aspartate on LH increase was time dependent. When
subjects drank sodium D-aspartate for 6 days, LH
increased only 1.07-fold, and this value was not statisti-
cally significant (Table 1). However, when the treatment
of D-Asp was continued for 12 consecutive days, the LH
concentration in the serum increased significantly (bene-
fit effects). In order to know how long LH remained
increased in the blood after the suspension of the treat-
ment, we measured the concentration of LH in the serum
3 days after the D-Asp treatment or the placebo treatment
was suspended. The results indicated that 3 days after sus-
pension of D-Asp treatment, LH was still found at a 1.14-
fold increased levels compared with the respect of basal
level, but not statistically significant (Table 1).
Concerning the effect of D-Asp on the induction of testo-
sterone release, after 12 days of D-Asp treatment, the lev-
Typical HPLC analysis of D-Asp and other amino acids from rat pituitary gland Figure 1
Typical HPLC analysis of D-Asp and other amino acids from rat pituitary gland. Panel A, HPLC profile of amino 
acids from a standard mixture consisting of 50 pmoles of D-Asp and 100 pmoles of various L-amino acids. Panel B is the HPLC 
analysis of the same amino a cids, but after treatment with D-AspO. Panel C shows the HPLC analysis of free amino acids from 
0.05 mg of rat hippocampus, and panel D is the same sample, but after treatment with D-AspO. The peak of D-Asp disap-
peared completely after incubation of the sample with D-AspO (panels B and D), indicating that the peak area of D-Asp was 
completely due to D-Asp.
02468 1 0 1 2 1 4 1 6
0
20
40
60
80
100
R
e
l
a
t
i
v
e
f
l
u
o
r
e
s
c
e
n
z
e
Elution time (min)
L
-
A
s
p
L
-
G
l
u
D-Asp
Other amino acids
02468 1 0 1 2 1 4 1 6
0
20
40
60
80
100
R
e
l
a
t
i
v
e
f
l
u
o
r
e
s
c
e
n
z
e
Elution time (min)
L
-
A
s
p
L
-
G
l
u
D-Asp
Other amino acids
02468 1 0 1 2 1 4 1 6
0
20
40
60
80
100
R
e
l
a
t
i
v
e
f
l
u
o
r
e
s
c
e
n
z
e
Elution time (min)
L
-
A
s
p
L
-
G
l
u
D-Asp
Other amino acids
02468 1 0 1 2 1 4 1 6
0
20
40
60
80
100
R
e
l
a
t
i
v
e
f
l
u
o
r
e
s
c
e
n
z
e
Elution time (min)
L
-
A
s
p
L
-
G
l
u
D-Asp
Other amino acids
A
B
C
D
Standard
Standard + D-AspO
Rat hippocampus
Rat hippocampus + D-AspOReproductive Biology and Endocrinology 2009, 7:120 http://www.rbej.com/content/7/1/120
Page 6 of 11
(page number not for citation purposes)
els of testosterone in the serum of the participants were
significantly increased compared with basal levels. Out of
23 participants, 20 had increased testosterone. From a
mean of 4.5 ± 0.6 ng/ml serum at zero time, it rose to 6.4
± 0.8 ng/ml, a 42% increase (Table 1). Statistical analyses
indicated a significant effect [ANOVA with repeated meas-
ures: treatment effect: F(1,82) = 7.724, p < 0.0082] and a sig-
nificant interaction between treatment and days [F(2,82) =
32.599; P < 0.0001]. As with LH, so also with testosterone,
the effect of D-aspartate was time dependent. When sub-
jects were treated with sodium-D-aspartate for only 6
days, testosterone was found of 1.15-fold higher than
basal levels, but this increase was not statistically signifi-
cant (Table 1). Interestingly 3 days after the suspension of
D-Asp treatment, testosterone was still increased 1.22-fold
compared with the basal levels (5.8 ± 0.6 ng/ml against
4.5 ± 0.6 ng/ml). Fisher's post-hoc analysis also revealed a
significant difference in the testosterone concentration in
the serum 3 days after the end of the treatment (p < 0.01)
(Table 1). One plausible explanation of this phenomenon
is that since in rats ingested D-Asp remains accumulated
in the testes in significant amounts until 3 days after the
suspension of D-Asp treatment (see below), if it is
assumed that in humans D-Asp also remains significantly
increased in the testes 3 days after the suspension of D-
Asp treatment, we can deduce that in humans as in rats, D-
Asp had remained accumulated in significant amounts in
the testes and consequently it continued to stimulate tes-
tosterone release.
Effects of D-aspartate on the release of LH and 
testosterone in rats
When rats drank a solution of 20 mM sodium D-aspartate
for 12 days, the concentration of LH and testosterone in
the serum increased significantly. After treatment, the
level of LH in the rats' serum was increased by 51% com-
pared with that of the controls. From a mean LH value of
3.7 ± 0.3 mIU/ml for the controls, it increased to a value
of 5.6 ± 0.4 mIU/ml, a 1.51-fold increase (p < 0.001)
(Table 2). Three days after the suspension of the treat-
ment, LH concentration still remained increased com-
pared with the control rats but the difference was not
statistically significant (Table 2).
Concerning testosterone, the effect of sodium D-aspartate
on testosterone release in rat serum was to induce a 2.05-
Table 1: Effects of D-aspartate on LH and testosterone release in human serum
Basal levels treatment After 6 days of D-Asp 
treatment
After 12 days of D-Asp 3 days after the 
suspension of D-Asp
LH (mIU/ml serum)
Subjects treated with with 
Na-D-aspartate
4.2 ± 0.5 4.5 ± 0.6 5.6 ± 0.9* 4.8 ± 0.8
Subjects treated with 
placebo
4.2 ± 0.4 4.3 ± 0.7 4.2 ± 0.6 4.1 ± 0.5
Testosterone (ng/ml serum)
Subjects treated with Na-D-
aspartate
4.5 ± 0.6 5.2 ± 0.7 6.4 ± 0.8* 5.8 ± 0.6*
Subjects treated with 
placebo
4.6 ± 0.5 4.5 ± 0.7 4.7 ± 0.7 4.6 ± 0.7
These results are the mean ± SEM of LH and testosterone in serum of 23 participants (aged 27-37 years) at zero time (basal levels), after 6 days and 
12 days of D-aspartate treatment and 3 days after the suspension of treatment. Subjects drank a daily dose of DADAVIT® (Na-D-aspartate). The 
placebo treatment was carried out on another 20 participants of the same age, who drank a daily dose of DADAVIT® placebo. Statistical analysis 
was conducted using ANOVA with repeated measures (post-hoc test). * Values are statistically significant for p < 0.001.
Table 2: Effects of D-aspartate on LH and testosterone release in rat serum
Rats treated with placebo Rats treated with Na-D-Aspartate for 
12 days
Rat treated with Na-D-Asp for 12 days and 
then for 3 days with placebo
LH
(mIU/ml serum)
3.7 ± 0.3 5.6 ± 0.4* 4.1 ± 0.3
Testosterone
(ng/ml serum)
5.1 ± 0.4 10.4 ± 1.2* 6.1 ± 0.5*
A group of 10 male rats (120-130 days old) were allowed to drink a solution of 20 mM NaCl. A second group of rats were allowed to drink a 
solution of 20 mM of Na-D-aspartate for 12 days and a third group of rats were allowed to drink 20 mM Na-D-aspartate for 12 days and then tap 
water for 3 days. After treatment each rat was sacrificed and LH and testosterone in serum determined. Values are the mean ± SEM). Asterisks 
indicate that the difference in the value between treated rats and control rats was significant at p < 0.001, evaluated by one-way ANOVA.Reproductive Biology and Endocrinology 2009, 7:120 http://www.rbej.com/content/7/1/120
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fold increase of this hormone; from a basal level of 5.1 ±
0.8 ng/ml in the control rats, testosterone reach the level
of 10.4 ± 1.2 ng/ml in treated animals (p < 0.001) (Table
2). It is interesting to observe that, contrary to what
occurred with LH, three days after the suspension of the
treatment, testosterone levels still remained significantly
increased compared with the control rats: a 1.27-fold
increase (p < 0.01) (Table 2).
The effect of D-Asp on the increased release of testoster-
one in serum that occurs 3 days after suspension of the
treatment may be due to two events: i) the increase of tes-
tosterone in serum is a consequence of the increased LH,
which in turn stimulates the release of testosterone in the
testes; and ii) D-Asp also has a direct action on the testes
in enhancing testosterone release, as already demon-
strated both previously [5,13] and also by this study (see
below). In addition, since the ingested D-Asp also still
remains accumulated significantly in the testes 3 days
after D-Asp suspension of treatment (this study), we
deduce that the persistent increase of testosterone in rat
blood is due to the accumulation of D-Asp that persists
leading to stimulated testosterone production.
Occurrence and accumulation of D-aspartate in rat tissues 
following D-Asp treatment
The results obtained from this experiment demonstrated
that D-Asp occurs naturally at a comparatively higher con-
centration in the pituitary gland, where the mean concen-
tration was found to be 129 ± 12 nmol/g tissue (Table 3),
followed by the testes (109 ± 8 nmol/g tissue), followed
by other tissues (Table 3). After treatment with D-Asp for
12 days, D-Asp was found to be accumulated in all the rat
tissues examined (Table 3). However, the pituitary, the
testes and the thyroid were the tissues in which this amino
acid was accumulated in the greatest amounts. In the pitu-
itary, in fact, D-Asp was increased 6.8-fold compared with
the basal levels (Table 2). In the testes D-Asp was
increased 7.15-fold compared within to the basal levels.
However we found that in all rat tissues 12 hours after
from D-Asp treatment, D-Asp was found accumulated at a
level that was 2-3 times greater than the basal levels (Table
3).
Effects of D-aspartate on the synthesis of LH and cGMP in 
the isolated rat pituitary
In vitro experiments carried out on the isolated pituitary
gland demonstrated that when the gland is incubated
with 0.1 mM D-Asp, a significantly increased (1.8-fold)
the synthesis of LH occurs. In fact, whereas the control
sample contained an LH value of 250 ± 8 mIU/mg pro-
tein, in the sample incubated with D-Asp, the LH concen-
tration rose to 480 ± 11.4 mIU/mg, p < 0.001) (Fig. 2, left
panel). The same effects occurred also when the concen-
tration of D-Asp in the medium was 1.0 mM. In this case
the increased LH synthesis was enhanced 2.32-fold (from
250 ± 8 mIU/mg of protein to 580 ± 19.7 mIU/mg) (A, B:
p < 0.001; a, b: p < 0.02), but the increase was not propor-
tionate to the concentration of D-Asp (Fig. 2, left panel).
In this experiment we also measured the concentration of
cAMP and cGMP in the medium in which the pituitary
gland was incubated with D-Asp and found that the con-
centration of cGMP was significantly increased. A concen-
tration of 0.1 mM D-Asp in 60 min of incubation induced
a significant increase in the synthesis of cGMP it raised
2.5-fold, from a value of 1.0 ± 0.2 pmol/mg tissue to 2.5
± 0.4 pmol/mg tissue (Fig. 2, right panel). D-Asp at the
concentration of 1.0 mM in the medium induced a 3.1-
fold increase in the synthesis of cGMP (A, B and C, D: p <
0.0001) (Fig. 2, right panel). However, the increase was
not proportional to D-Asp concentration, thus indicating
that the minimum concentration of 0.1 mM is already suf-
ficient to stimulate the pituitary to synthesize cAMP; this
is similar to the effects of other described molecules on
the pituitary gland [27-29].
Table 3: Endogenous occurrence of D-aspartate in rat tissues and accumulation after treatment with sodium D-aspartate
Basal levels of D-Asp Levels of D-Asp after 12 days of D-Asp 
treatment
Levels of D-Asp 3 days after the suspension of 
D-Asp treatment
Pituitary 129 ± 12 880 ± 45* 145 ± 12
Testes 109 ± 8 780 ± 45* 205 ± 14*
Thyroid 90 ± 6 350 ± 19* 110 ± 9
Hippocampus 62 ± 5 108 ± 9* 78 ± 7
Frontal cortex 41 ± 4 85 ± 7* 55 ± 5
Liver 12 ± 3 24 ± 2* 11 ± 3
Kidney 10 ± 2 45 ± 4* 13 ± 3
Serum 4 ± 1 8 ± 2* 3 ± 1
A group of 10 male rats (120-130 days old) rats were allowed to drink 20 mM sodium D-aspartate for 12 days. A second group of 10 male rats of 
the same age were allowed to drink 20 mM sodium D-aspartate for 12 days and then drink tap water for 3 days. A third group of 10 rats male rats 
of the same age drank 20 mM of NaCl for 12 days (placebo). All rat were sacrificed and collected serum and solid tissues and determined the 
concentration of D-Asp. Values are the mean ± SEM. Asterisks indicated that the difference between treated animals and control were statistically 
significant for a p < 0.001 evaluated by one-way ANOVA.Reproductive Biology and Endocrinology 2009, 7:120 http://www.rbej.com/content/7/1/120
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Effects of D-aspartate on the synthesis of testosterone and 
cAMP in rat Leydig cells
When Leydig cells obtained from rat testes were incubated
with 0.1 mM D-Asp, there was a significant 2.4-fold
increase in the synthesis of testosterone. From a basal
value of 34 ± 3 ng testosterone/106 in Leydig cells, after D-
Asp treatment, testosterone was raised to 82 ± 3 ng/106
cells (A, B: p < 0.001) (Fig. 3, left panel). When the con-
centration of D-Asp was 1.0 mM in the medium, the
increase was 2.94-fold compared with the control (C, D: p
< 0.001) (Fig. 3, left panel). Thus, as occurred with LH
synthesis in the pituitary gland, in Leydig cells the concen-
tration of 0.1 mM D-Asp also induced testosterone syn-
thesis significantly. We looked for the action of D-Asp on
the second messenger and found that following treatment
of Leydig cells with 0.1 mM D-Asp, cAMP was increased
3.1-fold compared with the control. When D-Asp was
administered at a levels of 0.1 mM in the medium, from a
value of 20 ± 3.0 pmol/106 in Leydig cells in the control,
cAMP rose to 62 ± 8.1 pmol/106 (p < 0.001) (Fig. 3, right
panel). When D-Asp was administered at a level of 1.0
mM in the medium, a 5.25-fold increase was observed (20
± 3.0 pmol/106 compared with 105 ± 3.3 pmol/106 after
stimulation) (p < 0.0001) (Fig. 3, right panel). These
results thus mirrored the previously reported data in
which it was demonstrated that the stimulation of Leydig
cells is accompanied by an increase in cAMP [30].
Biosynthesis of D-aspartate in rat tissues: D-aspartate 
racemase
The presence of D-Asp in rat tissues leads to the question
of the origin of D-Asp. In order to determine whether D-
Asp is biosynthesized in vivo by conversion of L-Asp to D-
Asp, we incubated a sample homogenized with L-Asp and
then measured the D-Asp generated. We have termed the
enzyme which converts L-Asp into D-Asp "D-aspartate
racemase". The results obtained from this investigation
have demonstrated that this enzyme is present in many rat
tissues, and that of the investigated tissues (pituitary, tes-
tes, brain, liver, kidney and serum), the pituitary gland is
the tissue which contains the highest enzymatic activity,
with 20 ± 3.0 EU/mg protein, followed by: testis; brain,
liver, kidney and serum (Fig. 4). In addition, it is also
interesting to observe that the D-aspartate racemase activ-
ity is greater in those tissues in which D-Asp also occurs at
the higher levels.
Discussion
In this study using a specific HPLC method combined
with the use of D-AspO (Fig. 1) and specific immunoen-
Effects of D-Asp on LH and cGMP synthesis in isolated rat pituitary glands Figure 2
Effects of D-Asp on LH and cGMP synthesis in isolated rat pituitary glands. Pituitary glands were incubated at 37°C 
for 60 min in a medium with Na-D-aspartate 0.1 or 1.0 mM and then LH and cGMP levels were determined in the total gland 
homogenate plus medium. The left panel shows that the increase of LH (LH synthesis) due to the action of the two concentra-
tions of D-Asp versus the control (pituitary incubated without D-Asp): A, B (p < 0.001); a, b (p < 0.02). The right panel shows 
the total concentration of cGMP determined in the same samples as above obtained (cGMP synthesis): A, B and C, D(p < 
0.001). Results are the mean ± SEM obtained from 5 individual experiments. Asterisks indicate that the difference in value 
between treated rats and control rats was significant at p < 0.0001, evaluated by one-way ANOVA.
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zymatic methods for the determination of LH and testo-
sterone as well as of the second messengers, cAMP and
cGMP, we have demonstrated that D-aspartic acid plays a
role in the release and synthesis of LH and testosterone in
humans and rats. In humans we found that with the con-
sumption of a daily dose of 10 ml of 2 M sodium D-aspar-
tate solution (3.12 g) for 12 consecutive days, the levels of
LH and testosterone in the serum were significantly
increased, by 33% and 42% respectively. In 87% of the
subjects who have been treated with sodium D-aspartate
increased the concentration of LH and testosterone in the
serum (p < 0.0001). After 6 days of treatment LH was
already found to have increased, but this increase was not
statistically significant (Table 1). Three days after sodium
D-aspartate suspension, LH still was found higher than
that of basal levels (a 1.14-fold increased), but this
increase was not statistically significant (Table 1), indicat-
ing that the increase of LH was dose dependent. The con-
sumption of sodium D-aspartate in humans also induced
significant testosterone release in the serum. In fact, in the
same subjects who took D-Asp for 12 days, the levels of
testosterone increased significantly. ANOVA with
repeated measurements indicated a significant value (p <
0.0001). As with LH, so also with testosterone, 6 days of
treatment induced increased serum testosterone in the
blood, but this increase was not significant. Interestingly,
contrary to what occurred for LH, three days after suspen-
sion of the treatment, testosterone still remained
increased in the serum 1.28-fold increase compared with
the basal levels, and this increase was significant (p <
0.01) (Table 1). A possible explanation of this event is
that the ingested D-Asp probably also remained accumu-
lated in the testes 3 days after treatment was stopped, and
it continued to stimulate the testosterone production in
the testes. This hypothesis is supported by results
obtained in rats. In fact, after rats had drunk a solution of
20 mM D-Asp for 12 days, this amino acid had accumu-
lated in various tissues, especially the pituitary and the tes-
tes (Table 3). However, when D-Asp treatment was
suspended, D-Asp that had accumulated in tissues dimin-
ished until it reached basal levels, except in the testes,
where D-Asp still remained significantly increased 1.88
fold (Table 3).
In this study we used rats as model animals in order to
understand the molecular mechanism by which D-Asp
induce its action. Rats were allowed to drink a solution of
sodium D-Asp for 12 days and after that the concentration
of D-Asp that accumulated in tissues was determined
along with the concentration of LH and testosterone. In
rat as in humans, D-Asp also actively induced LH and tes-
tosterone release. In fact, when rats were treated with D-
Effects of D-Asp on the synthesis of testosterone and cAMP in isolated rat Leydig cells Figure 3
Effects of D-Asp on the synthesis of testosterone and cAMP in isolated rat Leydig cells. 1 ml of purified Leydig cells 
(1.0 × 106 cells) was incubated at 37°C for 60 min with Na-D-Asp 0.1 or 1.0 mM and control and then the testosterone and 
cAMP synthesis was determined. The left panel shows the total production of testosterone in the medium plus the Leydig cell 
homogenate, in the control sample and in the samples incubated with 0.1 mM or with 1.0 mM D-Asp: A, B and C, D (p < 
0.001). The right panel shows the concentration of cAMP in the same above samples: A, B and C, D (p < 0.001). Values are the 
mean ± SEM obtained from 5 individual experiments. Asterisks indicate that the increased levels were significant compared 
with the controls at p < 0.001 as evaluated by one-way ANOVA.
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Asp, a significant increase in LH and testosterone was
observed after the 12 days of treatment (Table 2), coincid-
ing with the increased levels of D-Asp in the pituitary and
testis respectively (Table 2). Thus, these data indicate that
D-Asp is involved in the regulation of the above hor-
mones.
In vitro experiments conducted on an isolated rat pituitary
incubated with D-Asp demonstrated that D-Asp at the
concentration of 0.1 mM in the medium is capable of
inducing the synthesis of LH (Fig. 2, left panel) and testo-
sterone (Fig. 3, left panel). In addition, when the pituitary
gland was incubated with 0.1 mM D-Asp, a significant
increase of cGMP occurred in the assay mixture (Fig 3,
right panel) thus indicating that the release and synthesis
of LH occurred under the intervention of the cGMP. These
data are in agreement with previous results obtained by
other investigators [27-29], who demonstrated that the
molecule involved in the signal transduction for other
metabolites in the rat pituitary was cGMP. Similarly, in
vitro experiments conducted on isolated Leydig cells incu-
bated in a medium containing 0.1 mM of sodium D-Asp
demonstrated that this amino acid is capable of inducing
the synthesis of testosterone (Fig. 3, left panel) and that
this event is mediated by cAMP, which acts as the mole-
cule involved in the signal transduction for testosterone
synthesis from rat Leydig cells (Fig. 3, right panel). Also,
this last result is in agreement with previous studies by
other investigators in which it was demonstrated that the
increase of testosterone synthesized by Leydig cells occurs
under the intervention of the cAMP [30]. The final con-
cern of this study was to examine the biosynthesis of D-
Asp in the pituitary and testis. The results demonstrated
that rat tissues contain a racemase activity that is capable
of converting L-Asp into D-Asp. We have termed this
enzyme "D-aspartate racemase" and it is present in all the
rat tissues we analyzed. The pituitary and the testis are the
tissues with higher concentrations (Fig. 4). These data
thus indicate that a relationship exists between the endog-
enous concentration of D-Asp and the concentration of
the D-aspartate racemase in the tissues (Fig. 4).
In this study, we also investigated the action of L-Asp on
hormone release in rats. A group of 10 male rats were
treated with L-Asp instead of D-Asp at the same time and
at the same concentration and then levels of LH and tes-
tosterone in the blood were determined. The results of
this investigation indicated that the L-Asp does not induce
any significant increase of serum LH or testosterone (data
not shown), thus indicating thus that only the stereo-
chemical form of D-Asp is active in the hormone release.
Conclusion
Here we demonstrated that D-aspartic acid, which occurs
as a physiological compound in the mammalian pituitary
and testis, has a role in the regulation of the release and
synthesis of LH and testosterone. In humans and rats,
sodium D-Asp treatment enhances the release of LH and
testosterone. The experiments that we carried out on rats
have permitted us to understand that this amino acid reg-
ulates the synthesis of LH and testosterone in the pituitary
and the testis respectively. This action is mediated in the
pituitary by cGMP and in the testis by cAMP, which act as
the second messengers in the signal transduction in the
pituitary and testes respectively. The pituitary and testis
possesses a D-Aspartate racemase, which provides the nec-
essary production of D-Asp.
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D-Aspartate racemase activity in rat tissues: Synthesis of D- Asp Figure 4
D-Aspartate racemase activity in rat tissues: Synthe-
sis of D-Asp. Homogenized tissue were incubated with L-
Asp for 60 min at 37°C and then the amount of D-Asp syn-
thesized was detected. The D-Asp that developed was deter-
mined by a colorimetric method based on the use of D-
AspO. One enzyme unity (EU) was defined as the amount of 
the enzyme capable of generating 1 nmol of D-Asp in 60 min 
of incubation at 37°C and in the above assay conditions. The 
specific activity was defined as the EU/mg protein. The values 
are the mean ± SEM as obtained from five determinations, 
each carried out on a different rat.
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